iShares International Treasury Bond ETF vs Illumina, Inc. — how do they compare? iShares International Treasury Bond ETF trades at $41.3, while Illumina, Inc. trades at $190.38 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IGOV | ILMN | |
|---|---|---|
52-Week High | $43.09 | $205.10 |
52-Week Low | $40.35 | $91.00 |
Market Cap | — | $29.12B |
Sector | — | Health |
Enterprise Value | — | $30.48B |
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $41.13, down 0.15% on the day, with a bullish technical signal driven by moving averages despite neutral oscillators. The stock shows consolidated trading near key support at $41. Financial data remains limited, but recent news highlights significant exposure to global bond market volatility through its ETF structure.
The outlook is clouded by interest rate sensitivity and inflationary pressures, posing downside risks. Investment appeal hinges on macroeconomic stability, while the primary opportunity lies in potential yield curve normalization benefiting long-duration assets.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Trailing returns across standard periods
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →